About Novavax
Novavax is a publicly listed company based in Gaithersburg (United States) founded in 1987. Novel vaccines are developed using nanoparticle and matrix adjuvant technology. It operates in the Healthcare and Technology sectors. The company has 952 employees. Novavax has completed 2 acquisitions, including Isconova and PRAHA VACCINES. Its chief executive, as recorded, is John Jacobs. Its website novavax.com draws about 46 thousand monthly visits. Novavax offers products and services including Matrix-M Adjuvant and Recombinant Nanoparticle Vaccine Technology. Its focus areas include Life Sciences, Immunotherapy, Vaccine and Therapeutic. Its competitors include Adaptive Biotechnologies, Moderna and Generate Biomedicines; 3 of its 3 listed competitors have raised funding.
Company details
Novavax was founded in 1987 and is headquartered in Gaithersburg, United States. Vaccines are developed by the company in the biotechnology sector, focusing on recombinant nanoparticle platforms and adjuvant technology. The pipeline encompasses candidates for respiratory syncytial virus, coronavirus, malaria, Ebola, and seasonal quadrivalent influenza. Operations center on advancing these vaccine technologies for global health needs.
- Headquarters Gaithersburg, United States
- Employees 952
- Stage Public
- SectorsHealthcareTechnology
- Website category Finance · Investing
- Email••••••••
- Phone•••• ••••
- Website novavax.com
- Social LinkedIn X
- Legal Name Novavax, Inc.
Products & Services of Novavax
Novavax offers a comprehensive portfolio of products and services, including Matrix-M Adjuvant and Recombinant Nanoparticle Vaccine Technology.
Enhances immune response in vaccines for infectious diseases
Develops protein-based vaccines for global health protection
Funding Insights of Novavax
- Total Rounds 15
- Last Round Post-IPO — $84.5M
- First Round $1.07M
(Feb 2005)
- Investors Count 12
Latest 10 of 15 funding rounds of Novavax with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2023 | $84.5M | Post-IPO | – | – | |
| Jul 2020 | $1.6B | Grant | – | – | |
| Jun 2020 | $200M | Post-IPO | – | – | |
| Jun 2020 | $60M | Grant | – | – | |
| May 2020 | $384M | Post-IPO | – | – | |
| Mar 2020 | $4M | Post-IPO | – | – | |
| Jan 2017 | $217,097 | Grant | – | – | |
| Jan 2016 | $300M | Post-IPO | – | – | – |
| Sep 2015 | $89M | Grant | – | – | |
| Jul 2012 | $2M | Grant | – | – |
12 investors in total: 12 institutional.
Investors in Novavax
Novavax has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, Gates Foundation and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare investments are targeted by this private equity firm. | 2017 | cepi.net | Oslo, Norway | |
| innkap.se | ||||
Innovative vaccines are developed and manufactured by SK bioscience. | 2018 | skbioscience.com | Seongnam-si, South Korea | |
Government entity focused on information and services | 2000 | usa.gov | United States | |
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States | |
Military forces are provided by the U.S. Department of Defense for national security. | defense.gov | Washington, D.C., United States | ||
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Charitable foundation investments on poverty reduction and healthcare | 2000 | gatesfoundation.org | Seattle, United States | |
Global health solutions are developed and delivered to enhance outcomes. | 1977 | path.org | United States | |
| niaid.nih.gov |
Investor details for Novavax
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Novavax
304 people are tracked at Novavax (163 in leadership, 9 in board & advisors, 132 in team); the tracked headcount is 952.
| Name | Role | Group |
|---|---|---|
John Jacobs | CEO & President | Leadership |
Stanley C Erck | CEO | Leadership |
Alexandra Parnell | Senior Director - Clinical/non-clinical And Labeling | Leadership |
Donna Hinckley | Associate Director Of Finance | Leadership |
Rachel Summers | Sr. Director, Product Safety And Pharmacovigilance | Leadership |
Anna McSorley | Senior Director, Clinical Quality Assurance | Leadership |
Olivia Chua | General Manager, Region APAC | Leadership |
Felipe Alcorta | Director, Financial Systems & Administration | Leadership |
Elaine O’Hara | Executive Vice President & Chief Strategy Officer | Leadership |
John C. Jacobs | President & CEO | Leadership |
Jim Kelly | EVP, CFO & Treasurer | Leadership |
Rick Crowley | EVP, COO | Leadership |
Jim Cho | Director Global Supply Chain Production Planning | Leadership |
John Dinka | Director, Drug Product Process Engineering And Facility Design | Leadership |
Allison Jumic | Director, Global Risk Management, Global Vaccine Safety | Leadership |
Mary Anne Anderson | Vice President Global Program Management | Leadership |
Dana W. | Regulatory Program Manager, Associate Director | Leadership |
Erica Porter | Associate Director - Analytical Technical Services | Leadership |
Jasdeep K. | Senior Director, Fp&a And G&a | Leadership |
Patricia Tsang | Associate Director, EHS Management Systems | Leadership |
284 more people are available in the full profile.
Complete people profiles for Novavax
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Novavax
Novavax is a publicly listed company on the NASDAQ with ticker symbol NVAX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date08 Dec 1995
- Listed onNASDAQ: NVAX
- Listed entityNovavax, Inc.
- Exchange sectorHealth technology
- ISINUS6700024010
- Share price$12.82 (+1.26% on the day) · 2026-10-13
- Market capitalisation$2.11B
- Price to earnings3.9
- EPS (diluted, trailing year)$-1.52
- Volume (last session)8,399,728
Financials of Novavax
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $1.12B | $440.3M | $590.9M |
| 2024 | $682.2M | -$187.5M | -$183.5M |
| 2023 | $983.7M | -$545.1M | -$373.8M |
| 2022 | $1.98B | -$657.9M | -$615.7M |
| 2021 | $1.15B | -$1.74B | -$1.67B |
Detailed financial statements for Novavax
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Novavax
Novavax has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Isconova and PRAHA VACCINES.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Serums and vaccines are developed and produced by PRAHA VACCINES. | prahavaccines.cz | Kutna Hora, Czech Republic | 2017 | May 2020 | $167M | |
Vaccine adjuvants are developed for infectious diseases and veterinary applications. | isconova.com | Uppsala, Sweden | 1999 | Jun 2013 | $29.6M |
Complete acquisition details for Novavax
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Novavax
6 dated milestones of Novavax across 36 years, from founding to its latest funding, stage changes and deals.
- Founded Novavax is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $1.1M.
- Acquisition Acquires Isconova.
- Acquisition Acquires PRAHA VACCINES.
- Funding Latest funding round, Post-IPO, of $84.5M.
Competitors of Novavax
Novavax has 3 listed competitors in our database, 3 of them funded. They include Adaptive Biotechnologies, Moderna and Generate Biomedicines.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| adaptivebiotech.com | 2009 | Seattle, United States | $419.15M | 609 | Clinical diagnostics and drug discovery for immune diseases are provided. | |
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| generatebiomedicines.com | 2018 | Somerville, United States | $643M | 286 | Developer of novel protein-based therapeutics using machine learning and biological engineering |
Detailed competitors of Novavax
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Novavax
The website of Novavax (novavax.com) receives about 46K visits a month and ranks #977,850 among all websites worldwide, #8,844 in Investing.
- Monthly visits46K
▲ 37.2% vs previous month
- Unique visitors15.8K
per month
- Global rank#977,850
among all websites
- Category rank#8,844
Finance · Investing
- Bounce rate53%
- Pages per visit1.6
- Average visit27 sec
- DevicesDesktop 44% · Mobile 56%
Websites whose visitors overlap most with Novavax. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| ycharts.com | 100% | 897.5K | #49,773 | View details | |
| talkmarkets.com | 95% | 429.9K | #145,348 | View details | |
| trefis.com | 95% | 290.2K | #198,777 | View details | |
| directorstalkinterviews.com | 95% | #594,029 | View details | ||
aaii.com | aaii.com | 95% | #111,389 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 11 similar websites and full traffic analytics for Novavax
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Novavax (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Novavax
Complete news archive for Novavax
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Novavax
Novavax was founded in 1987 and raised its 1st funding round 18 years after it was founded.
Novavax is headquartered in Gaithersburg, United States. It is registered at Gaithersburg, Maryland, United States.
John Jacobs is the CEO of Novavax, as recorded in our data.
Novavax has 952 employees.
Annual revenue of Novavax is $1.12B as on Dec 31, 2025.
Novavax was founded in 1987 and is headquartered in Gaithersburg, United States. Vaccines are developed by the company in the biotechnology sector, focusing on recombinant nanoparticle platforms and adjuvant technology. The pipeline encompasses candidates for respiratory syncytial virus, coronavirus, malaria, Ebola, and seasonal quadrivalent influenza. Operations center on advancing these vaccine technologies for global health needs.
Novavax's top competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines.
Novavax offers Matrix-M Adjuvant and Recombinant Nanoparticle Vaccine Technology.
Yes, Novavax is publicly traded on NASDAQ under the ticker symbol NVAX.
Novavax has made 2 acquisitions, including Isconova, and PRAHA VACCINES.
Novavax has 12 investors. Key investors include NIH, Gates Foundation, HHS, Path, and RA Capital.